在注射多D,L-乳酸 (PDLLA) 后的颗粒瘤用氨治疗
Kateryn Michelle Perez Willis1, Rosario Ramirez Galvez2
1Department of Dermatology, Derma Laser KPW Medical Center, Lima, Peru.
Case reports in dermatological medicine
|May 3, 2024
概括
聚-D,L-乳酸 (PDLLA) 生物刺激器可以引起类似于花粉瘤的反应. 静脉注射的三氨和口服的普雷尼松有效地解决了这些罕见的患者的不良事件.
科学领域:
- 化品皮肤学 化品皮肤学
- 皮肤病理学 皮肤病理学
- 再生医学是一种再生医学.
背景情况:
- 生物刺激剂,如聚-D,L-乳酸 (PDLLA),越来越多地用于化品程序,以刺激原蛋白合成.
- 虽然通常是安全的,但在PDLLA注射后,罕见的不良事件,如结节和颗粒瘤可能会发生.
研究的目的:
- 报告在PDLLA应用后发生的颗粒瘤样反应.
- 描述使用内溶性三诺和口服普得尼松的这种不良事件的成功管理.
主要方法:
- 一名45岁的女性因皮肤松而接受了PDLLA注射.
- 在注射后4个月,她出现了面部胀和可触摸的结节,与颗粒瘤一致.
- 治疗包括内注射三氨 (每月两次) 和口服普雷迪尼松的逐渐减缓疗程.
主要成果:
- 临床检查和超声波证实了注射部位的多个结节.
- 经过四次内溶性氨和口服普雷尼松治疗,患者的不良反应完全消失.
- 超声波显示结节的分离.
结论:
- 类似颗粒瘤的反应很少见,但可能与PDLLA生物刺激剂相关的不良事件.
- 内溶性皮质类固醇注射,结合口服类固醇,代表了有效的治疗策略来管理这种反应.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160